Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1016/j.cell.2011.10.022">http://dx.doi.org/10.1016/j.cell.2011.10.022</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Sun Feb 17 18:19:42 EST 2019</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/85646">http://hdl.handle.net/1721.1/85646</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits

Nicolas Chevrier,1,2,3,4 Philipp Mertins,1 Maxim N. Artyomov,1,6 Alex K. Shalek,7 Matteo Iannacone,5,9 Mark F. Ciaccio,8 Irit Gat-Viks,1,6,10 Elena Tonti,5,9 Mariela M. DeGrace,1,2,3 Karl R. Clauser,1 Manuel Garber,1 Thomas M. Eisenhaure,1,2 Nir Yosef,1,6 Jacob Robinson,7 Amy Sutton,7 Mette S. Andersen,7 David E. Root,7 Ulrich von Andrian,5 Richard B. Jones,8 Hongkun Park,7 Steven A. Carr,1 Aviv Regev,1,6,12 Ido Amit,1,2,3,6,11,12,* and Nir Hacohen1,2,3,12,*

1Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
2Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA 02129, USA
3Department of Medicine
4Graduate Program in Immunology, Division of Medical Sciences
5Immune Disease Institute and Department of Pathology
Harvard Medical School, Boston, MA 02115, USA
6Howard Hughes Medical Institute, Department of Biology, MIT, Cambridge, MA 02142, USA
7Departments of Chemistry, Chemical Biology, and Physics, Harvard University, Cambridge, MA 02138, USA
8The Ben May Department for Cancer Research and the Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL 60637, USA
9Division of Immunology, Infectious Diseases and Transplantation, San Raffaele Scientific Institute, Milan 20132, Italy
10Present address: Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
11Present address: Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
12These authors contributed equally to this work
*Correspondence: ido.amit@weizmann.ac.il (I.A.), nhacohen@partners.org (N.H.)
DOI 10.1016/j.cell.2011.10.022

SUMMARY

Deciphering the signaling networks that underlie normal and disease processes remains a major challenge. Here, we report the discovery of signaling components involved in the Toll-like receptor (TLR) response of immune dendritic cells (DCs), including a previously unknown pathway shared across mammalian antiviral responses. By combining transcriptional profiling, genetic and small-molecule perturbations, and phosphoproteomics, we uncover 35 signaling regulators, including 16 known regulators, involved in TLR signaling. In particular, we find that Polo-like kinases (Plk) 2 and 4 are essential components of antiviral pathways in vitro and in vivo and activate a signaling branch involving a dozen proteins, among which is Tnfaip2, a gene associated with autoimmune diseases but whose role was unknown. Our study illustrates the power of combining systematic measurements and perturbations to elucidate complex signaling circuits and discover potential therapeutic targets.

INTRODUCTION

Signaling networks detect and respond to environmental changes, and defects in their wiring can contribute to diseases. For example, Toll-like receptors (TLRs) sense microbial molecules and trigger signaling pathways critical for host defense (Takeuchi and Akira, 2010). Genetic defects in components of the TLR and other pathogen-sensing pathways have been linked to human diseases. Hence, rational targeting of these pathways should help in better manipulating immune responses associated with infections, autoimmunity, and vaccines (Hennessy et al., 2010).

However, despite extensive studies, many components of TLR and other biological networks are unknown, and many genes associated with disease have not been assigned to a function or a pathway. A key challenge is thus to systemically dissect mammalian signaling networks, by determining the functions of their components and placing them within pathways. Previously, we introduced an integrated experimental and computational approach to decipher the TLR transcriptional network of immune dendritic cells (DCs) (Amit et al., 2009), allowing us to identify transcriptional regulators and to define their impact on TLR responses in DCs. For example, we found a host of cell-cycle regulators—Rbl1, Rb, Myc, Jun, and E2fs—that are required for antiviral transcriptional responses in nondividing DCs.

Here, we adapt and expand this approach to the discovery and validation of TLR signaling components in DCs (Figure S1 available online). First, to identify candidate components, we rely on transcriptional feedbacks, whereby a signaling circuit regulates the transcript levels of genes encoding some, but not all, of its components (Amit et al., 2007; Fraser and Germain, 2009; Freeman, 2000). Second, we perturb these candidates with shRNAs and measure the effects on a representative
signature of >100 TLR-activated genes. Third, we use functional phosphoproteomics to expand the pathway’s scope to components whose mRNA levels may be unchanged upon TLR activation. Applying this approach iteratively, we discovered 19 functional components, including a signaling arm mediated by two Polo-like kinases (Plk2 and 4) that participate in regulating well-established host antiviral pathways.

RESULTS

Transcripts for Signaling Components Are Regulated upon TLR Stimulation

To identify candidate components of pathogen-sensing pathways, we used genome-wide mRNA profiles, previously measured at 10 time points along 24 hr following stimulation of primary bone marrow-derived DCs (BMDCs) with lipopolysaccharide (LPS; TLR4 agonist), polyinosinic:polycytidylic acid (poly(I:C); recognized by TLR3 and the cytosolic viral sensor (Amit et al., 2009). These three TLRs activate transcriptional programs referred to here as “inflammatory” (TLR2), “antiviral” (TLR3), or both (TLR4) (Figure 1A) (Amit et al., 2009; Doyle et al., 2002).

Our analysis uncovered 280 genes annotated as known or putative signaling molecules that were differentially expressed following stimulation: 115 kinases, 69 phosphatases, and 96 other regulators, such as adaptors and scaffolds (Figure 1B, Table S1, and Experimental Procedures). These 280 genes were enriched for canonical pathways of the TLR network such as MAP kinase (p < 1.22 × 10−10, overlap 25/87, hypergeometric test), TLR (e.g., Myd88, Traf6, Iκκα, Ikβ1; p < 8.43 × 10−12, 21/86), and PI3K (p < 2.58 × 10−8, 11/33) pathways, as well as the PYK2 pathway (p < 3.12 × 10−10, 12/29), which was recently associated with the TLR system (Wang et al., 2010). Overall, 94 of the 280 genes (33%) were associated with the TLR network in the literature (Table S1), supporting the validity of our candidate selection strategy. The remaining 186 genes (67%) represent candidate TLR components. To test their putative function in TLR signaling, we selected a subset of 23 candidates based on their strong differential expression and to proportionally represent the five main induced expression clusters (Figures 1B and 1C). We also selected six canonical TLR components (Myd88, Mapk9, Ikβ1, Iκκα, Tank, and Map3k7) as benchmarks (Figures 1A and 1D).

A Perturbation Strategy Places Uncharacterized Signaling Components within the Antiviral and Inflammatory Pathways

We perturbed our 6 positive controls and 17 of the 23 candidates in BMDCs using shRNA-encoding lentiviruses (6 candidates showed poor knockdown efficiency) (Table S1). We stimulated the cells with LPS and used a multiplex mRNA counting method to measure the effect of gene silencing on the mRNA levels of 118 TLR response signature genes, representing the inflammatory and antiviral programs (Figure 2A). Notably, the expression of the 118 genes was not affected in BMDCs transduced with lentivirus compared to untransduced cells (Amit et al., 2009). We determined statistically significant changes in the expression of signature transcripts upon individual knockdowns based on comparison to 10 control genes, whose expression remains unchanged upon TLR activation, and to control shRNAs (Experimental Procedures). Finally, we associated signaling molecules and downstream transcriptional regulators that may act in the same pathway by comparing the perturbational profiles of the 23 signaling molecules (6 canonical and 17 candidates) to each other and to those of the 123 transcriptional regulators (including transcription and chromatin factors and RNA-binding proteins) previously tested (Figures 2 and S2 and Table S2) (Amit et al., 2009).

Perturbing 5 of the 6 canonical signaling molecules strongly affected the expression of TLR signature genes, consistent with their known roles (Figure 2A and Table S2) and validating our approach. For example, perturbing Myd88, a known inflammatory adaptor, specifically abrogated the transcription of inflammatory genes (e.g., Cxc11, II1a, II1b, Ptgs2, Tnf; Figure 2A), similar to perturbations of downstream inflammatory transcription factors (e.g., Nfkb1, Nfkbiz; Figure 2B). In addition, Tank acted as a negative regulator of a subset of antiviral genes (Figure 2A), as expected (Kawagoe et al., 2009), and Tbk1 knockdown affected both antiviral and inflammatory outputs (Figure 2A), consistent with findings that Tbk1 regulates NF-κB complexes (Barbie et al., 2009; Chien et al., 2006). Notably, Ikκκα (IKK-ε) knockdown did not affect our gene signature, consistent with previous observations that IKK-ε−−/− DCs respond normally to LPS and viral challenges (Matsui et al., 2006). Thus, IKK-ε may be either not functional or redundant in our system.

All of the 17 candidate signaling molecules tested, except Plk2 (discussed below), affected at least 6 of the 118 genes (on average, 16.6 targets ± 10.4 standard deviation [SD]), and 12 affected more than 10% of the genes (Figures S2A and S2D). Notably, perturbations of these 17 candidates did not affect BMDC differentiation (88.3% ± 6.8% SD of CD11c+ cells; Table S1). These effects are comparable to those of known signaling molecules and transcriptional regulators in this system (Figures S2B–S2E). For example, the receptor tyrosine kinase Met, not previously associated with TLR signaling, affected a number of signature genes similar to Tbk1 (Figures S2C and S2D), in both the inflammatory and antiviral programs (Figure 2A). Conversely, both the phosphatase Pptre and the adaptor Soc6 positively regulated the inflammatory program, although negatively regulating some antiviral genes (Figure 2B). Of the 17 candidates tested when we originally conducted this screen, 10 have subsequently been reported in other studies as functional in the TLR system (Table S1), providing an independent confirmation. For example, here Map3k8 knockdown affected both inflammatory and antiviral target genes (Figure 2A), consistent with its reported role in the TLR pathways based on Sluggish mice (Xiao et al., 2009).

We identified both primary (e.g., Myd88) and secondary (e.g., Stat1) mediators of TLR responses. Although secondary mediators are not part of the initial intracellular signaling cascade, they are important physiological components of the TLR response, and their perturbation can lead to phenotypic outcomes similar to those of primary components. For example, the receptor tyrosine kinase Mertk acted as both a positive and negative regulator of some inflammatory and antiviral genes (e.g., Ifnb1), respectively (Figure 2A), consistent with its reported role as a secondary inhibitor of the TLR pathways (Rothlin et al., 2007).
Figure 1. mRNAs of Signaling Components Are Differentially Regulated upon TLR Stimulation

(A) Simplified schematic of the TLR2, 3, and 4 pathways (Takeuchi and Akira, 2010).

(B) mRNA expression profiles of differentially expressed signaling genes. Shown are expression profiles for 280 differentially expressed signaling genes (rows) at different time points (columns): a control time course (no stimulation, Ctrl) and following stimulations with Pam3CSK4 (PAM), LPS, and poly(I:C). Tick marks: time point poststimulation (0.5, 1, 2, 4, 6, 8, 12, 16, 24 hr). Shown are genes with at least a 1.7-fold change in expression compared to prestimulation levels in both duplicates of at least one time point. The three leftmost columns indicate kinase (KIN), phosphatase (PSP), and signaling regulators (SIG) (black bars). Values from duplicate arrays were collapsed and gene-expression profiles were hierarchically clustered. The rightmost color-coded column indicates the five major expression clusters.

(C and D) mRNA expression profiles of candidate (C) and canonical (D) TLR signaling regulators selected for subsequent experiments. The color-coding of the gene names highlights the corresponding expression clusters from the complete matrix from (A).

See also Figure S1 and Table S1.
**Crkl Modulates JNK-Mediated Antiviral Signaling in the TLR Network**

Among the 17 candidate signaling proteins, perturbation of the tyrosine kinase adaptor *Crkl* decreased expression of 13% of the signature genes, especially antiviral ones (Figures 2A and S2D). *Crkl* belongs to several signaling pathways, including early lymphocyte activation (Birge et al., 2009), but has not been associated with the TLR network. *Crkl*’s perturbation profile closely resembled those of known antiviral regulators, most notably Jnk2 (*Mapk9*; Chu et al., 1999) (Figures 2A and 3A). Indeed, when *Crkl*−/− DCs were stimulated with LPS, the expression of antiviral cytokines (*Cxcl10*, *Ilfb1*) was strongly reduced (Figure 3B, left and middle), but that of an inflammatory cytokine (*Cxcl1*) was unaffected (Figure 3B, right).

To test whether *Crkl* is a primary component of the TLR pathway, we determined whether *Crkl* phosphorylation is rapidly modified after TLR signaling initiation. Using SILAC-based (Ong et al., 2002) quantitative phosphoproteomics, we identified and quantified 62 phosphotyrosine (pTyr)-containing peptides from BMDCs stimulated with LPS for 30 min (Figure 3C, Table S3, and Experimental Procedures). Of these 62 phosphopeptides, 7 and 9 were significantly up- or downregulated, respectively.

---

**Figure 2. A Perturbation Strategy Assigns Function to Signaling Components within the TLR Pathways**

(A) Perturbation profiles of 6 canonical (purple) and 17 candidate (blue) signaling components and 20 core TLR transcriptional regulators belonging to the inflammatory (orange) and the antiviral (green) programs. Shown are the perturbed regulators (columns) and their statistically significant effects (FDR < 0.02) on each of the 118 TLR signature genes (rows). Red: significant activating relation (target gene expression decreased following perturbation); blue: significant repressing relation (target gene expression increased following perturbation); white: no significant effect. The rightmost column categorizes signature genes into antiviral (light gray) and inflammatory (dark gray) programs.

(B) Functional characterization based on similarity of perturbation profiles. Shown is a correlation (Pearson) matrix of the perturbation profiles from (A). Yellow: positive correlation; purple: negative correlation; black: no correlation.

See also Figure S2 and Table S2.
Figure 3. Crkl Adaptor Functions in the Antiviral Arm of TLR4 Signaling

(A) Comparison of Crkl and Mapk9 knockdown profiles. Shown are the effects of Crkl and Mapk9 perturbation (columns) on the 118 signature genes (rows). Data were extracted from Figure 2A.

(B) Inhibition of transcription of antiviral cytokines in Crkl+/− BMDCs. Shown are mRNA levels (qPCR; relative to t = 0) for Ifnb1 (left), Cxcl10 (middle), and Cxcl1 (right) in three replicates per time point. Error bars represent the standard error of the mean (SEM) (n = 3 mice).

(C) Crkl phosphorylation is induced following LPS stimulation. Top: schematic depiction of experimental workflow. From left: Protein lysates from unstimulated (control) and LPS-treated BMDCs grown in "light" and "heavy" SILAC medium were mixed (1:1) and digested into peptides with trypsin before phosphotyrosine (pY) peptide enrichment by immunoprecipitation and LC-MS/MS analysis. Bottom: Shown are the differential phosphorylation levels (log 2 ratios, y axis) of all 62 phosphopeptides identified and quantified by LC-MS/MS (x axis). Black: peptides with more than 2-fold differential expression (left: induced; right: repressed). See also Table S3.
Figure 4. Plk2 and 4 Regulate the Antiviral Program

(A) Similarity of Plk2 and 4 mRNA expression profiles. Shown are mRNA levels (from Figure 1B) of Plk2 (left) and Plk4 (right) following stimulation with LPS (black) or poly(I:C) (gray). Error bars represent the SEM.

(B) Double knockdown of Plk2 and 4 represses the antiviral signature. Shown are significant changes in expression of TLR signature genes (rows) following double knockdown of Plk2 and 4. Red and blue mark significant hits as in Figure 2, only for genes where the effect was consistent between the two independent combinations of shRNAs.
Polo-like Kinases Are Critical Activators of the Antiviral Program

To discover potential drug targets among our 17 candidates, we next focused on Plk2, a well-known cell-cycle regulator and drug target (Strebhardt, 2010). The roles of Plks in nondividing, differentiated cells are poorly defined (Archambault and Glover, 2009; Strebhardt, 2010). We have previously shown that transcriptional regulators of cell-cycle processes (e.g., Rb1, Rb, Myc, Jun, E2f) are co-opted to function in the antiviral responses in DCs (Amit et al., 2009). However, neither knockdown (Figure 2A) nor knockout (Figure S3A) of Plk2 in BMDCs had any effect on the TLR response. We hypothesized that this could be due to functional redundancy with another Plk, as Plk4 mRNA was induced in DCs similarly to Plk2 (Figure 4A), albeit at a lower amplitude (and thus was below our threshold for inclusion in the initial candidate list). Interestingly, functional redundancy between Plk2 and 4 has been suggested to account for the viability of Plk2/4-1 (Zhang et al., 2010) and for an inflammatory cytokine (Cxcl1), following LPS stimulation in BMDCs using two independent combinations of shRNAs (Figures S4B and S4C). Importantly, BI 2536 treatment prestimulation impacted neither the viability nor the cell-cycle state of BMDCs (Figures S4D and S4E), suggesting that Plk inhibition does not act through cell-cycle effects. Consistent with our shRNA and BI 2536 perturbations, two other pan-Plk inhibitors—structurally unrelated to BI 2536—also repressed Ifnb1 and Cxcl10 expression without affecting Cxcl1 (Figure S4F). This strongly suggests that the effects induced by these perturbations are due to Plk inhibition and not off-target effects. Furthermore, we observed a similar inhibitory effect of BI 2536 on Ifnb1 induction in Ifnar^−/− and wild-type BMDCs, demonstrating that Plks act directly downstream of TLR activation and not in an autocrine/paracrine feedback loop mediated by IFN receptor signaling (Figure S4G). This is consistent with a recent phospho-proteomic study reporting an enrichment for Plk substrates as early as 15 min after LPS stimulation in macrophages (Weintz et al., 2010).

We next used confocal microscopy to monitor the effect of BI 2536 on the subcellular localization of IRF3, a key antiviral transcription factor. To more effectively deliver the drug, we plated BMDCs on vertical silicon nanowires (Shalek et al., 2010) precoated with BI 2536 prestimulation. Nanowires alone had no effect on the TLR response (Figures 5A and SSA). BI 2536
inhibited IRF3 nuclear translocation in a dose-dependent manner upon poly(I:C) or LPS stimulation, whereas the control JNK inhibitor SP 600125 had no effect (Figures 5B, 5C, and S5B). On the other hand, BI 2536 did not affect NF-κB p65 localization (Figures 5D and 5E). Notably, IRF3 translocation was also decreased when delivering BI 2536 in solution, but to a lesser extent compared to nanowire-mediated delivery (Figure S5C), highlighting the utility of highly efficient drug delivery methods.
to induce homogeneous effects in single-cell assays. Altogether, these results place Plk2 and 4 as critical regulators of the antiviral program, upstream of a major antiviral transcription factor.

**Plks Are Essential for Activation of All Well-Established IFN-Inducing Pathways in Conventional and Plasmacytoid DCs**

DCs can be broadly categorized into two major subtypes—conventional and plasmacytoid DCs—each relying on distinct mechanisms to induce type I IFNs and antiviral gene expression (Blasius and Beutler, 2010). In conventional DCs (cDCs), antiviral responses are activated through TLR4/3 signaling (via TRIF) or through the cytosolic sensors RIG-I or MDA-5 (via MAVS) (Figure 6A). In plasmacytoid DCs (pDCs; specialized IFN-producing cells), the antiviral response depends solely on endosomal TLR7 and 9 that signal via MYD88 (Figure 6A) (Blasius and Beutler, 2010; Takeuchi and Akira, 2010).

BI 2536 treatment showed that Plks are essential for the viral-sensing pathways in both cDCs and pDCs. In cDCs, BI 2536 inhibited the transcription of antiviral genes (Ifnb1 and Cxcl10) upon infection with each of four viruses: vesicular stomatitis virus (VSV; Figure 6B, top), Sendai virus (SeV; Figure S6A, top), Newcastle disease virus (NDV; Figure S6A, bottom) (all three sensed through RIG-I), and encephalomyocarditis virus (EMCV), sensed through MDA-5 (Figure 6B, bottom and Experimental Procedures). Notably, BI 2536 neither affected the mRNA level of Cxcl1 (an inflammatory cytokine) in any of the four cases nor affected the response to heat-killed Listeria monocytogenes, a natural TLR2 agonist (Figures 6B, S6A, and S6B). In pDCs, BI 2536 treatment nearly abrogated the transcription of mRNAs for the antiviral cytokines Ifnb1, Ifna2, and Cxcl10 after stimulation with type A CpG oligonucleotides (CpG-A) or infection with EMCV, sensed by TLR9 and 7, respectively (Figures 6C and S6C and Experimental Procedures). Conversely, in pDCs stimulated with CpG-B—a ligand known to activate inflammatory pathways but not IFN-inducing pathways—BI 2536 treatment decreased Cxcl10 mRNA, while moderately increasing Cxcl1 mRNA (Figure 6C). Finally, of our 118 signature genes, BI 2536 repressed genes induced by CpG-A alone or by both CpG-A and -B, although having a minor effect, if any, on CpG-B-specific genes in pDCs (Figure 6D and Table S5). These findings may help reveal the poorly characterized molecular determinants of IFN induction in pDCs (Reizis et al., 2011) and demonstrate a critical role for Plks across all well-known IFN-inducing pathways.

**Plks Are Essential in the Control of Host Antiviral Responses**

To assess the impact of Plk inhibition on the outcome of viral infection, we infected primary mouse lung fibroblasts (MLFs) with influenza virus. BI 2536-treated MLFs infected with influenza failed to produce interferon (Figure 6E) and showed elevated replication of both wild-type (PR8) and poorly replicating mutant (ΔNS1) viruses (Figure 6F). The reduced interferon response was not due to drug-induced toxicity (Figure 6G).

Next, we tested the effects of Plk inhibition in virally infected mice. BI 2536 exhibits good tolerability in mice (Streghardt, 2010), which its efficacy and safety in vivo, we tested whether BI 2536 would also affect the response to viral infection in animals. In mice infected with VSV, BI 2536 strongly suppressed mRNA production in popliteal lymph nodes for type I IFNs (Ifnb1, Ifna2) and Cxcl10 but did not affect Cxcl1 mRNA induction (all compared to vehicle control; Figures 6H and S6D). Concomitantly, VSV replication in the lymph node rapidly increased as reflected by elevated VSV RNA levels (Figure 6I), comparable to the observed phenotype of VSV-infected Ifnar1−/− mice (Iannacone et al., 2010). Because the VSV model used here type I IFNs are produced by both infected CD169+ subcapsular sinus macrophages and pDCs (Iannacone et al., 2010), we cannot distinguish whether Plk inhibition affects macrophages, pDCs, or both. Nevertheless, our results confirm the physiological importance of Plks in the host antiviral response in both ex vivo primary MLFs and in vivo mouse lymph nodes.

**Plks Affect the Phosphorylation of Dozens of Proteins Post-LPS Stimulation, including Known and Candidate Antiviral Regulators**

We next sought to discover the signaling pathways between Plks and antiviral gene transcription. We used microwestern arrays (MWAs) (Ciaccio et al., 2010) to measure changes in the phosphorylation and protein levels of 20 and 6 TLR pathway proteins, respectively, in BMDCs at each of 12 combinations of four time points (0, 20, 40, 80 min after LPS stimulation) and three perturbations (vehicle control, BI 2536, and negative control JNK inhibitor SP 600125) (Table S6). Although LPS stimulation alone led to the expected changes (e.g., early peak of phosphorylation for ERK1/2, p38, and Mapkapk2 and rapid degradation of IκBα; Figure 7A), BI 2536 surprisingly did not cause any significant changes (Figures 7A, S7A, and S7B). We therefore hypothesized that Plks could affect previously unrecognized regulators of IFN-inducing pathways and/or known regulators with no existing antibodies to specific phosphosites.

Next, we used SILAC-based unbiased phosphoproteomics (Figure 7B, top) (Villéon and Gygi, 2008) to compare the levels of phosphotyrosine, -threonine, and -serine peptides following stimulation with LPS (for 30 or 120 min) in BMDCs pretreated with BI 2536 versus those treated with vehicle (DMSO). We identified and quantified 5,061 and 5,997 phosphopeptides after 30 and 120 min, respectively, for a total of 10,236 individual phosphosites (Figure 7B and Table S6). BI 2536 substantially affected the TLR phosphoproteome, leading to a significant (p < 0.001) change in the level of 510 phosphopeptides derived from 413 distinct proteins (Figure 7B and Table S6). Further supporting our results, 35% (2489/7018) of the phosphosites we identified were recently reported in mouse bone marrow-derived macrophages treated with LPS (Weintz et al., 2010). A comparison of the phosphosites of known kinases showed similar overlaps between the three studies (Figure S7C, right).

The Plk-dependent phosphoproteins include several known regulators of antiviral pathways (e.g., Prdm1, Fos, Unc13d) (Crozat et al., 2007; Keller and Maniatis, 1991; Takayanagi et al., 2010; Zeller et al., 2008) and a number of novel regulators identified in the current study.
Figure 6. Plks Are Critical in the Induction of Type I Interferons In Vitro and In Vivo

(A) IFN-inducing pathways in cDCs and pDCs.

(B and C) BI 2536 inhibits mRNA levels for antiviral cytokines in response to diverse stimuli in cDCs and pDCs. Shown are Ifnb1, Cxcl10, and Cxcl1 mRNA levels (qPCR; relative to t = 0) in cells treated with BI 2536 (1 μM; white bars) or DMSO vehicle (black bars) in cDCs (B) infected with VSV (multiplicity of infection 862 Cell 147, 853–867, November 11, 2011 ©2011 Elsevier Inc.) and pDCs (C) infected with EMCV (poly(I:C)).

(D) Gene expression levels in primary pDCs treated with BI 2536 (1 μM) or DMSO vehicle. Shown are the expression levels of genes involved in the antiviral response.

(E) Relative mRNA levels for Ifnb1 and Cxcl10 in primary MLFs treated with EMCV (poly(I:C)) and BI 2536 (1 μM) or DMSO vehicle.

(F) Viral replication (Luc) and cell viability in cells treated with NS1 (MOI 2) and BI 2536 (1 μM) or DMSO vehicle.

(G) Caspase activity in cells treated with NS1 (MOI 2), PR8, and BI 2536 (1 μM) or DMSO vehicle.

(H) Relative mRNA levels for Ifnb1 and Cxcl10 in mouse cells treated with VSV (MOI 2) and BI 2536 (1 μM) or DMSO vehicle.

(I) Relative mRNA levels for Ifnb1 and Cxcl10 in mouse cells treated with BI 2536 (1 μM) or DMSO vehicle.
2002), as well as many additional protein candidates with no previously known function in viral sensing (Figure 7B and Table S6). Notably, proteins involved in the TBK1/lkK-c/IRF3 axis were detected and quantified, but their phosphorylation levels were unchanged upon Plk inhibition (Table S6), consistent with the MWA data. Conversely, Plk inhibition with BI 2536 decreased the phosphorylation levels of cell-cycle regulators of the Jun family of transcriptional regulators (i.e., Jund) that we previously found to be co-opted by antiviral pathways (Amit et al., 2009). BI 2536 treatment also decreased the phosphorylation levels of the mitotic kinases Nek6 and Nek7 (Figure 7B). The recent observation that the phosphorylation of Nek6 substrates is increased following LPS stimulation in macrophages (Weintz et al., 2010) indirectly corroborates our finding that Nek6 may be active in TLR signaling. To test the role of these Plk-dependent candidates, we returned to our shRNA perturbation-based approach.

**Plk-Dependent Phosphoproteins Affect the Antiviral Response**

We perturbed 25 Plk-dependent phosphoproteins (Table S7), using shRNA perturbation in BMDCs followed by qPCR and TLR gene signature measurements. These candidates satisfied three criteria: (1) there was no prior knowledge of their function in viral-sensing pathways; (2) their phosphoprotein levels were consistently up- or downregulated upon BI 2536 treatment (in two independent experiments); and (3) they had detectable mRNA expression and/or differential expression upon stimulation.

Of the 18 phosphoproteins showing efficient knockdown, 11 caused a significant decrease in Ifnb1 mRNA levels with a single shRNA (Sash1, Dock8, Nek6, Nek7, Nfatc2, and Ankrd17; Figure S7D) or with two independent shRNAs (Tnfaip2, Samsn1, Arhgap21, Mark2, and Zc3h14; Figure S7E). Decrease in Cxcl10 expression was less prominent, consistent with our previous observations of BI 2536’s weaker effect on this cytokine during LPS stimulation (Figures S7D and S7E, far right panels). Each of the 11 Plk-dependent phosphoproteins tested affected at least 9 targets in the 118-gene signature (on average, 39 targets ± 30 SD; Figure 7C), and 9 affected more than 10% of the targets in the TLR gene signature (Figure 7C).

Nine of the 11 Plk-dependent phosphoproteins affected the TLR signature comparably to major antiviral regulators (Figure 7D). For example, the knockdown profiles of Samsn1, Dock8, and Sash1 were closely correlated to those of Stat and Irf family members (Figure 7D), and those of Tnfaip2 and Zc3h14 were most correlated to the Plk2/4 double knockdown. Interestingly, Tnfaip2, a protein of unknown molecular function, has been associated with rheumatoid arthritis and autoimmune myocarditis in genome-wide association studies (Wellcome Trust Case Control Consortium, 2007; Kuan et al., 1999). Our findings provide a potential molecular context for this disease association.

**DISCUSSION**

Using an integrative strategy combining transcriptomics, genetic and chemical perturbations, and unbiased phosphoproteomics, we established a role for Plks in host defense pathways inducing type I IFNs, likely by controlling the phosphorylation and activity of a module of at least 11 components (Figure 7E). Our findings and approach open up several avenues for future investigations.

Consistent with our finding that cell-cycle transcription factors play a role in antiviral responses (Amit et al., 2009), we identified several cell-cycle kinases (Plks, Neks) as important regulators of these responses. Despite extensive studies on the role of Plk1 in mitosis, the functions of its paralogs—Plk2, 3, and 4—are poorly defined (Strebhardt, 2010). Although they are less essential than Plk1 in regulating cell division, their roles in nondividing cells such as neurons are emerging (Archambault and Glover, 2009; Seeburg et al., 2005). Interestingly, silencing of both Plk2 and 4 was required to reveal their importance in antiviral responses, highlighting the necessity of epistasis analysis in studying mammalian signaling networks. Although it is currently not feasible to screen for genetic interactions at a genome-wide scale, it will be interesting to develop innovative approaches to uncover them.

BI 2536 blocked the nuclear translocation of IRF3 without affecting its phosphorylation level (based on MWAs and phosphoproteomics). A similar phenomenon has been reported for NF-kB (Ye et al., 2011). This suggests that IRF3 translocation in our system is likely to be regulated by a mechanism that does not impact phosphorylation.

Furthermore, Plk inhibition suppresses type I IFN production in vivo during viral infection—a finding that has potential clinical implications. Indeed, disease activity in patients with Systemic Lupus Erythematosus (SLE) correlates with IFN expression signatures (Banchereau and Pascual, 2006), and lupus-prone mice exhibit reduced symptoms upon treatment with a dual inhibitor of TLR7 and 9 (Barratt and Coffman, 2008) or deletion
Figure 7. Unbiased Phosphoproteomics Identifies a Plk-Dependent Antiviral Pathway

(A) BI 2536 does not affect phosphorylation and protein levels of known TLR signaling nodes. Shown are representative MWA (see Experimental Procedures) blots (left) obtained from analyzing lysates from BMDCs pretreated with DMSO, BI 2536 (1 μM), or SP 600125 (5 μM) and stimulated with LPS for 0, 20, 40, and
of the IFN receptor (Santiago-Raber et al., 2003). Thus, testing the effect of BI 2536 on a mouse model of lupus will be key to assess the potential therapeutic implications of Plk inhibition for SLE.

Our approach may be applicable for characterizing the functions of genes reported in genome-wide association studies (e.g., Tnfaip2), for uncovering potential therapeutic targets (e.g., Plks), and for repurposing existing small molecules in new physiological contexts (e.g., using the cancer drug BI 2536 to repress innate immune responses). The vast public compendia of microarray data could serve as starting points for identification of relevant signaling components in diverse biological systems, followed by perturbations and signature measurements. Nevertheless, because the mRNAs corresponding to many pathway components do not change upon pathway activation, our approach is far from exhaustive. Combination of our perturbation-based approach with large-scale biochemical measurements (e.g., posttranslational modifications, protein-protein interactions) will lead to more comprehensive, integrated maps of signaling and transcriptional networks.

**EXPERIMENTAL PROCEDURES**

**Cells and Mouse Strains**

BMDCs were generated from 6- to 8-week-old female C57BL/6J mice, Crlk mutant mice (Jackson Laboratories), Plk2<sup>−/−</sup> mice (Elian Pharmaceuticals), or Ifnar1<sup>−/−</sup> mice (gift from K. Fitzgerald). Primary MLFs were from C57BL/6J mice.

**Viruses**

Self/strain Cantell and EMCV strain EMC (ATCC), NDV strain Hitchner B1 (gift from A. Garcia-Sastre), and VSV strain Indiana (U. von Andrian) were used for infections. Influenza A virus strain A/PR/8/34 and SeV strain Cantell and EMCV strain EMC (ATCC), NDV strain Hitchner B1 (gift from K. Fitzgerald), and B/Chile/1/1974 (H5N1) was from Invivogen. *Listeria monocytogenes* and *E. coli* were from HKLM. Heat-killed 1585 CpG type A, and ODN 1668 CpG type B) and Enzo Life Sciences infections. Influenza A virus strain A/PR/8/34 and SeV strain Cantell and EMCV strain EMC (ATCC), NDV strain Hitchner B1 (gift from K. Fitzgerald), and B/Chile/1/1974 (H5N1) was from Invivogen. *Listeria monocytogenes* and *E. coli* were from HKLM. Heat-killed 1585 CpG type A, and ODN 1668 CpG type B) and Enzo Life Sciences infections.

**Reagents**

TLR ligands were from Invivogen (Pam3CSK4, ultra-pure E. coli K12 LPS, ODN 1585 CpG type A, and ODN 1668 CpG type B) and Enzo Life Sciences (poly(I:C)). Heat-killed *Listeria monocytogenes* (HKLM) was from Invivogen. Polo-like kinase inhibitors were from Selleck (BI 2536), Sigma (GW843682X), and Chembridge (Poloxipan). SP 600125 (Jnk inhibitor) was from Enzo Life Sciences.

**mRNA Isolation, qPCR, and Microarrays**

Total or poly(A)<sup>+</sup> RNA was extracted and reverse transcribed prior to qPCR analysis with SYBR Green (Roche) in triplicate with GAPDH for normalization. For microarray analysis, Affymetrix Mouse Genome 430A 2.0 Array was used.

**shRNA Knockdowns**

High-titer lentiviruses expressing shRNAs were obtained from The Broad RNAi Platform and used to infect BMDCs as previously described (Amit et al., 2009).

**mRNA Measurements on nCounter**

5 × 10<sup>6</sup> BMDCs were lysed in RLT buffer (Qiagen) with 1% β- ME. Ten percent of the lysate was used for mRNA counting using the nCounter Digital Analyzer (NanoString) and a previously generated CodeSet of 118 genes (Amit et al., 2009). To score target genes whose expression is significantly affected by shRNA perturbations, we used a fold threshold corresponding to a false discovery rate (FDR) of 2%. Heatmaps and distance matrix analyses were generated using the Gene-E software (http://www.broadinstitute.org/cancer/software/GENE-E/).

**Detection of Regulated Signaling Genes**

We identified differentially regulated signaling components (i.e., kinases, phosphatases, and signaling adaptors or scaffolds) based on probesets reproducibly displaying at least 1.7-fold up- or downregulation in at least one time point, compared to unstimulated controls, using our previously published microarray dataset (NCBI GEO GSE17721, Amit et al., 2009).

**Nanowire-Mediated Drug Delivery and Microscopy**

BMDCs were plated on top of etched silicon nanowires (Si NWs) coated with small molecules. After 24 hr, cells were stimulated and processed for immuno-fluorescence analysis by confocal microscopy.

**VSV Infection Model**

Eight-week-old C57BL/6 male mice received 500 µg of BI 2536 (or vehicle) intravenously and 50 µg into the footpad 3 hr before and 2 hr after infection with 10<sup>6</sup> pfu of VSV into the footpad. Mice were sacrificed 6 hr post-infection, and the draining popliteal lymph nodes were harvested in RNAlater solution.

**Phosphotyrosine and Global Phosphopeptide Analysis**

Tyrosine-phosphorylated peptides from BMDC lysates were prepared using a PhosphoScan Kit (Cell Signaling Technology) and analyzed by data-dependent LC-MS/MS using a Thermo LTQ-Orbitrap. Quantitative analysis of
serine-, threonine-, and tyrosine-phosphorylated peptides was performed using SCX/IMAC as described (Villén and Gygi, 2008) with some modifications. Peptide samples were analyzed on a LTQ-Orbitrap Velos (Thermo Fisher Scientific). To identify and quantify peptides, mass spectra were processed with Spectrum Mill software package (Agilent Technologies) v4.0b, including in-house developed features for SILAC quantitation and phosphosite localization, and with MaxQuant (v1.0.13.13) (Cox and Mann, 2008) and Mascot search engine (v2.2.0, Matrix Science).

ACCESSION NUMBERS

Complete microarray datasets are available in the NCBI Gene Expression Omnibus (accession number GSE28520). Proteomics raw data are in the the Tranche data repository (https://proteomecommons.org/tranche/, hash: HTLY5ZeSLMhYyEfjJREklqLx6BxZczuixy9Jnlsync5HCkKx/8gB7nZKpGocwOnt8vOk/Q3c3ph/yCd/2L70AAAAAAAUeEq = =, and pass-phrase: SpSTB6vcSUKeNqefq59).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures, seven figures, and seven tables and can be found with this article online at doi:10.1016/j.cell.2011.10.022.

ACKNOWLEDGMENTS

We thank the members of the Hacohen and Regev laboratories, O. Takeuchi, B. Beutler, D. Mathis, P. Anderson, L. Gimlicher, and D. Bartel for valuable discussions and comments; L. Gaffney and L. Solomon for assistance with figures and artwork; and S. Gupta and the Broad Genetic Analysis Platform for microarray processing. This work was supported by NIH grant U54 AI057159, the NIH New Innovator Award DP2 OD002230 (N.H.), and NIH P50 HG006193 (A.R., N.H.); a Ph.D fellowship from the Boehringer Ingelheim Fonds (N.C.); the Human Frontier Science Program Organization and a Claire and Emanuel G. Rosenblatt Award from the American Physicians Fellowship (N.C.); the Human Frontier Science Program Organization and a Claire and Emanuel G. Rosenblatt Award from the American Physicians Fellowship (N.C.); the Human Frontier Science Program Organization and a Claire and Emanuel G. Rosenblatt Award from the American Physicians Fellowship (N.C.); the Human Frontier Science Program Organization and a Claire and Emanuel G. Rosenblatt Award from the American Physicians Fellowship (N.C.).

REFERENCES


Wellcome Trust Case Control Consortium. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678.

